March 22, 2018 08:16 AM EDT

Sun Pharma screeches to the psoriasis finish line with FDA OK of Ilumya. Too bad rivals J&J and others beat them to it

Brittany Meiling

In the crowded race to launch new therapies for psoriasis, India’s largest drugmaker Sun Pharma hustled to the finish line Thursday with FDA approval of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sun Pharma screeches to the psoriasis finish line with FDA OK of Ilumya. Too bad rivals J&J and others beat them to it

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Sun Phar­ma screech­es to the pso­ri­a­sis fin­ish line with FDA OK of Ilumya. Too bad ri­vals J&J and oth­ers beat them to it

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Sun Pharma screeches to the psoriasis finish line with FDA OK of Ilumya. Too bad rivals J&J and others beat them to it

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?